-
Poniard Pharmaceuticals Shares Slammed
Monday, November 16, 2009 - 9:01amPoniard Pharmaceuticals, Inc. (NASDAQ: PARD) today announced that its Pivotal Phase 3 SPEAR trial of Picoplatin did not meet primary endpoints. The trial was conducted with the U.S. Food and Drug Administration (FDA) under a special Protocol Assessment. Today, MPM Capital and Bay City Capital are...
Read More >>
